What Ancient Plague Can Teach Us About the Body's Defenses

A discovery near Lake Baikal in Siberia has changed the story of plague. Researchers found evidence that it caused deadly outbreaks among hunter-gatherers about 5,500 years ago, long before the medieval Black Death. The discovery also raises a broader question: why might people respond differently to a severe infection?

ReBalU approaches that question by looking at inherited differences, the body's current antioxidant resources, and nutrition. Its proposed framework combines testing with a food-based approach intended to support butyrate production in the colon and supply DHA from marine microalgae.

The main idea. Fighting infection and protecting the body from damage are related, but they are not the same job. ReBalU's intended role is to support the body's condition. It has not been demonstrated to prevent or treat plague.

This article explains the science behind that idea without requiring a background in genetics. It distinguishes what researchers have found from what still needs to be tested.

What the ancient discovery tells us

Macleod and colleagues examined ancient remains from four cemeteries near Lake Baikal and detected the plague bacterium in 18 of 46 people studied, about 39 percent. Their combined evidence from DNA, burial patterns, family relationships and dating supports two periods of lethal outbreaks, with children particularly affected.

That percentage is not a death rate for the surrounding population. It tells us how often the researchers detected plague DNA in the remains they studied, not how many living people were infected or survived.

The ancient bacteria differed from later plague strains and lacked some features associated with efficient flea-borne spread. They retained a gene associated with unusually broad immune activation. The researchers proposed that this could have contributed to severe illness, but they did not prove that explanation.

The important consumer lesson is that an infection can damage the body through both the germ itself and the body's response. The ancient findings do not tell us whether the victims had low antioxidant reserve, or whether a modern nutrition program would have protected them.

Your defenses need both an attack team and a cleanup team

Immune cells use reactive chemicals to help fight microbes, while antioxidant systems help control those chemicals and protect the body's own cells. Scientists call the balance between these chemical reactions redox.

Think of a fire crew using powerful equipment. Enough force is needed to put out the fire, but the surrounding building also needs protection. In the body, the aim is not to remove every reactive molecule, because some are useful for defense and signaling.

Modern laboratory studies of plague show that infection can damage mitochondria, the energy-producing structures inside cells, and change the production of reactive oxygen molecules. Those molecules can contribute to bacterial control and also to damage within the infected cell.

This is why the ReBalU idea is more specific than taking more antioxidants. Its research question is whether supporting the body's resources can help maintain useful defense while limiting unnecessary injury.

What reserve means in everyday language

In this framework, reserve means the resources and capacity the body has available when demand rises. A helpful analogy is a rechargeable battery: the design of the battery matters, but so do its current charge, condition and workload.

Genes can be thought of as part of that design, while measured markers provide clues about the current condition. A DNA result and a current blood or stool result answer different questions, and neither is a complete picture of health.

Redox reserve is a research concept here, not a single validated clinical number. A person should not be labeled weak solely because of a common gene variant, and this framework cannot currently calculate someone's chance of surviving plague.

The five ReBalU markers, explained simply

The proposed panel contains exactly five markers. They look at different parts of the picture rather than repeating the same measurement five times.

SOD2: a first step in protecting the cell's power supply

SOD2 is an enzyme, a protein that performs a chemical job, inside mitochondria. It changes a reactive oxygen molecule called superoxide into hydrogen peroxide, which other defense systems then need to handle.

Different versions of the SOD2 gene can affect how the enzyme reaches mitochondria, but the result depends on more than the gene alone. In the ReBalU naming convention, TT means Val/Val, TC means Val/Ala, and CC means Ala/Ala. These are inherited versions, not diagnoses.

Consumer meaning. The proposed SOD2 measurement asks about one part of cellular defense. Genotype, the amount of protein, and how well the enzyme works are different results, and none alone proves that a person is protected from infection.

Total glutathione: how much of an important resource is available

Glutathione helps cells manage reactive chemicals, and the body has systems for restoring it after use. Total glutathione measures the size of a pool in a particular sample, but it does not independently show how much is in the ready-to-use form or how efficiently it is being recycled.

Think of it as checking supplies in a storeroom. Counting the supplies is useful, but it does not tell you how quickly workers can use them or restock them.

Consumer meaning. A total-glutathione result is a clue about available resources, not a complete antioxidant strength score. Sample handling and the laboratory's method matter, because glutathione can change after the sample is collected.

Butyrate: a substance your gut microbes help make

Butyrate is made when gut microbes ferment suitable dietary material in the colon. Cells lining the colon use much of it locally, and the intestine and liver process it before smaller amounts reach the rest of the circulation.

The ReBalU concept is intended to feed this natural production process rather than supply sodium butyrate as a finished ingredient. Its discussed formulation uses tagatose, Fibersol-2 and high-methoxyl pectin as components of that substrate-based approach.

Consumer meaning. This marker relates to the gut's production and use of butyrate. A stool result measures what remains after production and absorption, so a higher or lower result cannot automatically be interpreted as better or worse.

DHA: a building material for cell membranes

DHA is an omega-3 fatty acid that can contribute to cell membranes and serve as starting material for substances involved in resolving inflammation. ReBalU's proposed DHA source is marine microalgal oil.

Think of DHA as a useful building material rather than a switch that automatically turns inflammation off. Supplying the material is not the same as proving that the body makes enough of the finished substances, or that a particular illness improves.

Consumer meaning. A DHA result can help describe fatty-acid status. The omega-3 index is a related but different measurement, because it includes both EPA and DHA in red blood cells, not DHA alone.

TKTL1: a research clue about how cells are behaving

TKTL1 is a protein being studied in connection with cell metabolism, meaning how cells process fuel and manage their activities. Its exact function and usefulness as a marker remain under investigation.

The method matters. Measuring TKTL1-related material inside certain immune cells is not the same as measuring it in the liquid part of blood, and inflammation can affect some TKTL1-related test results, making interpretation more complicated.

Consumer meaning. In this framework, TKTL1 is an exploratory clue, not a direct measurement of glutathione recycling. A result does not by itself diagnose plague, cancer or low reserve.

What the ReBalU protocol is intended to do

The proposed approach follows a test, support and retest cycle. Its goal is to look at inherited differences and current markers, provide nutritional inputs, and then see whether measurable changes occur.

The gummy concept combines substrates intended to support endogenous butyrate production with DHA-containing microalgal oil. Endogenous simply means produced within the body, in this case with the help of gut microbes, rather than administered as a finished butyrate product.

The companion mouthwash is conceived as an oral-mucosal and microbiome component. Its effects need to be evaluated separately. It is not established as a disinfectant against plague or a way to deliver treatment to infected lung cells.

The delivery distinction matters. Feeding microbial production in the colon differs from directly administering sodium butyrate, because production, location, absorption and metabolism differ. Studies of one approach should not automatically be presented as proving either benefit or harm from the other.

Research in human immune cells and mice supports the idea that butyrate can influence antimicrobial functions, but that work did not test the complete ReBalU formulation or show that it protects people from plague. Likewise, DHA's role in inflammation biology does not establish disease-specific benefit from a particular product.

The intended effect is therefore to support conditions for host resilience. Claims that the protocol selectively eliminates infected cells, improves antibiotic tolerance, or prevents severe plague would require direct evidence.

Why genes are not a verdict

SOD2 is a useful example of why inherited differences deserve study without becoming labels. Published work describes differences in mitochondrial handling between variants, but clinical associations vary with the condition and treatment being studied.

A TT result therefore does not mean someone has a broken immune system. A CC result does not guarantee high reserve or freedom from severe infection.

The most useful research question combines the inherited version with the person's measured condition. The ancient Baikal study does not establish that plague explains present-day antioxidant-gene differences between ancestry groups.

For consumers, the principle is simple. Look at the individual, not a broad ethnic label. Ask what a test actually measures, and whether that measurement has been shown to predict the outcome being claimed.

How this relates to the recent Russian reports

Reports reviewed on October 5, 2026 described a death and precautionary medical observation in Russia's Irkutsk region. However, Russia's public-health agency reported pneumonia of unknown cause, and the reviewed accounts did not establish publicly confirmed secondary plague transmission or identify a strain.

Pneumonia describes a lung illness. It does not by itself identify the germ. Bubonic plague generally involves swollen lymph nodes, while pneumonic plague affects the lungs and can spread through infectious droplets during close contact.

Pneumonic plague is not described by the CDC as prolonged airborne spread of the type associated with measles. The CDC distinguishes its close-contact respiratory-droplet transmission from that kind of airborne transmission.

Would the same ReBalU idea apply? If the illness were confirmed as plague, the broad research interest in host defense, mitochondrial function and available antioxidant resources would remain relevant. That would not prove that the protocol works against that infection, or that the five-marker panel predicts who becomes severely ill.

The reports are a reason to ask careful questions, not evidence that ReBalU has succeeded or failed. The ancient findings and the current news should not be merged into a single confirmed story.

What a consumer should take away

Testing should explain, not frighten. The five-marker idea looks at different parts of the body's condition, but it is not currently a validated plague-risk score. A result needs a clear explanation of its specimen, method and limits.

Nutrition and treatment have different jobs. ReBalU is being discussed as a host-support framework, not a demonstrated way to kill the plague bacterium. Suspected plague requires prompt medical assessment and appropriate antibiotics, and nutrition does not replace that treatment.

A changed marker is not automatically a changed health outcome. Showing that a formulation alters a laboratory result is one step. Showing that people recover better or experience fewer complications is another.

The central research question is understandable: can an individually measured, substrate-based nutrition approach improve the body's ability to handle stress? ReBalU proposes a way to investigate that question, while the answers about plague protection remain unproven.

Sources

1. Macleod et al., Nature, 2026, on the ancient Lake Baikal plague study.
2. Macleod et al., full article, Oxford University Research Archive.
3. Immune defense against plague, PMC.
4. NRF2 and antioxidant defenses, PMC.
5. Plague and mitochondrial injury, Microbiology Spectrum.
6. SOD2 genetic-variant study, PMC.
7. Measuring glutathione accurately, PMC.
8. Butyrate production and uptake, Obesity Reviews.
9. DHA and inflammation resolution, PMC.
10. Definition of the omega-3 index, Proceedings of the Nutrition Society.
11. TKTL1 function under investigation, Molecules.
12. TKTL1 measurement and inflammation, PMC.
13. Serum versus cell-associated TKTL1, PMC.
14. Butyrate and immune-cell function, PMC.
15. CNBC, October 5 reports from Russia.
16. CNN, on the diagnosis remaining uncertain.
17. CDC, plague questions and answers.
18. CDC, respiratory-droplet transmission.

This guide is consumer education from SOD Sciences Inc. It is for informational purposes only and is not medical advice. The markers, formulation and protocol described here are proposed and investigational.

This document presents a scientific hypothesis for discussion. The proposed intervention has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease, including plague. If you have symptoms of any infection, or have been told you may have been exposed, seek medical evaluation without delay. Nothing here is a reason to delay, decline or discontinue antibiotics or any other care you have been offered, and you should speak with your own physician before starting any supplement.